126 related articles for article (PubMed ID: 18042071)
21. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.
Bell KA; Smith Sehdev AE; Kurman RJ
Am J Surg Pathol; 2001 Apr; 25(4):419-32. PubMed ID: 11257616
[TBL] [Abstract][Full Text] [Related]
22. Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Pareja F; Selenica P; Brown DN; Sebastiao APM; da Silva EM; Da Cruz Paula A; Del A; Fu L; Weigelt B; Brogi E; Reis-Filho JS; Wen HY
Histopathology; 2019 Jul; 75(1):139-145. PubMed ID: 30843622
[TBL] [Abstract][Full Text] [Related]
23. A detailed morphological and immunohistochemical comparison of primary endometrial and tubo-ovarian high-grade serous carcinomas and their corresponding omental metastases.
Ruba S; Doherty D; Stewart CJR
Pathology; 2020 Feb; 52(2):197-205. PubMed ID: 31870502
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
25. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
Samaratunga H; Khoo K
Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
[TBL] [Abstract][Full Text] [Related]
26. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
[TBL] [Abstract][Full Text] [Related]
27. Cell polarity reversal in ovarian low-grade serous carcinomas and micropapillary serous borderline tumours: immunohistochemical observations.
Hui Y; Ou JJ; Sung CJ; Lawrence WD; Quddus MR
Histopathology; 2016 Nov; 69(5):892-894. PubMed ID: 27271798
[No Abstract] [Full Text] [Related]
28. An immunohistochemical panel to distinguish ovarian from uterine serous papillary carcinomas.
Zhang Y; Garcia-Buitrago MT; Koru-Sengul T; Schuman S; Ganjei-Azar P
Int J Gynecol Pathol; 2013 Sep; 32(5):476-81. PubMed ID: 23896709
[TBL] [Abstract][Full Text] [Related]
29. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
Kanner WA; Galgano MT; Stoler MH; Mills SE; Atkins KA
Int J Gynecol Pathol; 2008 Oct; 27(4):491-5. PubMed ID: 18753974
[TBL] [Abstract][Full Text] [Related]
30. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
31. Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers.
Collins LC; Carlo VP; Hwang H; Barry TS; Gown AM; Schnitt SJ
Am J Surg Pathol; 2006 Aug; 30(8):1002-7. PubMed ID: 16861972
[TBL] [Abstract][Full Text] [Related]
32. Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein.
Nassar H; Pansare V; Zhang H; Che M; Sakr W; Ali-Fehmi R; Grignon D; Sarkar F; Cheng J; Adsay V
Mod Pathol; 2004 Sep; 17(9):1045-50. PubMed ID: 15154007
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.
Schorge JO; Miller YB; Qi LJ; Muto MG; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Mar; 76(3):369-72. PubMed ID: 10684712
[TBL] [Abstract][Full Text] [Related]
35. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of Her2/neu, estrogen and progesterone receptors in invasive micropapillary carcinoma of the breast.
Kuroda H; Sakamoto G; Ohnisi K; Itoyama S
Breast Cancer; 2004; 11(3):301-6. PubMed ID: 15550850
[TBL] [Abstract][Full Text] [Related]
38. Stage IV micropapillary serous ovarian carcinoma: a report of three cases.
Kim YW; Srodon M; Bristow RE
Int J Gynecol Pathol; 2005 Jul; 24(3):235-8. PubMed ID: 15968198
[TBL] [Abstract][Full Text] [Related]
39. Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors.
Barbashina V; Corben AD; Akram M; Vallejo C; Tan LK
Hum Pathol; 2013 Aug; 44(8):1577-85. PubMed ID: 23517923
[TBL] [Abstract][Full Text] [Related]
40. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
